- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03797248
Prospective Cohort Study of Traditional Chinese Medicine for Survival of Patients With Early Breast Cancer
September 15, 2019 updated by: Ming-Yen Tsai, Chang Gung Memorial Hospital
The Clinical Outcome of Adjuvant Chemotherapy in Conjunction With Traditional Chinese Medicine in Breast Cancer Patients -a Observational Cohort Study
This 2-year trial is intended to be used to study breast cancer patients through forward-looking generation design through collaboration between Chinese and Western medical teams.
The whole study consists of 2 stages, stage I comprises a cross-sectional study-baseline and stage II is a cohort for outcome evaluation and follow-up study across a 3-year period.
To provide an empirical basis for combined TCM treatment in the Breast Cancer Research Team and to publish that as a reference for future TCM and Western medicine in integrative cancer treatment.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Breast cancer is a major health issue for women worldwide and has increased exponentially in the last decades.
Improved earlier detection combined with adjuvant systemic therapy is responsible for much of the reduction in cause-specific mortality from breast cancer.
Chemotherapy after surgery can decrease the risk of recurrence and is often used as routine treatment in clinic.
Because of the fact that a considerable number of patients seek for traditional Chinese medicine (TCM) during adjuvant chemotherapy, it is thus need to evaluate the correlation between TCM treatment and prognosis.
The investigators design a single center, prospective cohort study began in November 2018 in Kaohsiung, Taiwan.
A sample of 104 participants diagnosed with early breast cancer was recruited from Breast Cancer Research Team and are followed up every 3 to 6 months till October 2023.
Detailed information of participants includes general information, history of cancer, quality of life, side effects of chemotherapy and safety of treatment, body constitution of TCM and meridian energy analysis is taken face-to-face at baseline.
Study Type
Observational
Enrollment (Anticipated)
310
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ming-Yen Tsai, PhD
- Phone Number: +886975056534
- Email: missuriae@yahoo.com.tw
Study Locations
-
-
-
Kaohsiung, Taiwan, 83301
- Recruiting
- Kaohsiung Chang Gung Memorial Hospital
-
Contact:
- Ming-Yen Tsai
- Phone Number: +886975056534 +886975056534
- Email: missuriae@yahoo.com.tw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Patients with breast cancer aged over 20 years with histologically diagnosed stage 1-3 after radical surgery are enrolled from an academic medical center.
All participants need to complete the 6-8 cycle of adjuvant chemotherapy, which may last 6 months.
Description
Inclusion Criteria:
- Aged > 20 years old female patients;
- Patients with histologically proven stage 1-3 breast cancer after surgery;
- The duration from the end of radical surgery to the beginning of the trail is less than 1 month;
- ECOG score is 0-2 points;
- Agreed to participate in this study and signed informed consent.
Exclusion Criteria:
- Combined with inadequate heart, liver, kidney and hematopoietic function and other serious diseases;
- Pregnant and lactating women;
- Patients with a history of mental illness;
- Patients with distant metastasis and/or expected lifetime less than 3 months;
- Patients undergoing other medicinal herbs outside our hospital.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort 1
adjuvant chemotherapy combined with Chinese herbal medicine
|
All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
|
Cohort 2
adjuvant chemotherapy only
|
All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
disease-free survival
Time Frame: 3 years
|
3-year disease-free survival
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QOLs measurement-1
Time Frame: 6 months
|
Functional Assessment of Cancer Therapy - Breast Cancer(FACT-B)
|
6 months
|
QOLs measurement-2
Time Frame: 6 months
|
Eastern Cooperative Oncology Group (ECOG)
|
6 months
|
TCM pattern
Time Frame: 6 months
|
Body Constitution Questionnaire (BCQ)
|
6 months
|
meridian energy
Time Frame: 6 months
|
Meridian Energy Analysis Device (MEAD)
|
6 months
|
Side effects of adjuvant chemotherapy
Time Frame: 6 months
|
Common Terminology Criteria for Adverse Events (CTCAE)
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Chien-Ting Liu, MD, Division of Oncology, Department of Internal Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 12, 2018
Primary Completion (Anticipated)
October 24, 2020
Study Completion (Anticipated)
October 24, 2020
Study Registration Dates
First Submitted
January 5, 2019
First Submitted That Met QC Criteria
January 5, 2019
First Posted (Actual)
January 9, 2019
Study Record Updates
Last Update Posted (Actual)
September 17, 2019
Last Update Submitted That Met QC Criteria
September 15, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201801559A3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early-stage Breast Cancer
-
Dana-Farber Cancer InstituteCompletedEarly Stage Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage IIUnited States
-
Jonsson Comprehensive Cancer CenterDaiichi Sankyo Co., Ltd.; Translational Research in Oncology-U.SRecruitingInvasive Breast Cancer | Stage II Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Hormone Receptor Positive Breast Carcinoma | Early-stage Breast Cancer | Stage III Breast CancerUnited States
-
Tanvex BioPharma USA, Inc.CompletedBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Early-stage Breast CancerBelarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
-
Stanford UniversityTerminatedBreast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer Metastatic Breast CancerUnited States
-
Stanford UniversityNational Institutes of Health (NIH); University of California; Breast Cancer... and other collaboratorsActive, not recruitingBreast Cancer | Breast Cancer Non-invasive Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3)United States
-
Shandong Cancer Hospital and InstituteRecruitingEarly-stage Breast Cancer | Breast Conserving SurgeryChina
-
University of Wisconsin, MadisonRecruitingEarly-stage Breast CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingStage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Early-Stage Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
MedStar Franklin Square Medical CenterMedstar Health Research InstituteActive, not recruitingEarly Stage Breast CancerUnited States
-
Fudan UniversityHuazhong University of Science and Technology; LinkDoc Technology (Beijing)...RecruitingEarly-stage Breast CancerChina
Clinical Trials on Chinese herbal medicine
-
Guangzhou University of Traditional Chinese MedicineThe George InstituteNot yet recruitingIntracerebral HemorrhageChina
-
Center for Integrated CareUniversity of California, San Francisco; University of UtahRecruitingCoronavirus InfectionUnited States
-
Shengjing HospitalRecruitingPlasma Cell MastitisChina
-
Shanghai University of Traditional Chinese MedicineLonghua Hospital; Shanghai Putuo District Center HospitalCompletedType 2 Diabetes MellitusChina
-
Hong Kong Baptist UniversityRecruiting
-
Heilongjiang University of Chinese MedicineNot yet recruitingIn Vitro FertilizationChina
-
China Academy of Chinese Medical SciencesUnknownPrimary InsomniaChina
-
Taipei City HospitalNational Yang Ming UniversityCompletedLiver DysfunctionTaiwan
-
Chinese University of Hong KongUniversity of Maryland; National Center for Complementary and Integrative Health...CompletedIrritable Bowel SyndromeChina
-
Taipei City HospitalTaipei Medical University Shuang Ho HospitalCompletedBreast Cancer | Radiotherapy | Chinese Herbal MedicineTaiwan